Loading stock data…
$23.95+0.44 (+1.87%)
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair.
Surrozen, Inc. in the Healthcare sector is trading at $23.95 with a market capitalization of $349M. Wall Street consensus targets $48.40 (5 analysts), implying a +102.1% move over the next 12 months. The stock is currently 37% below its 52-week high of $37.83, remaining 3.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.00M | $5.00M↑ | $528,000↓ | $983,000 | $983,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.37M↑ | -$10.46M↑ | -$12.64M↓ | -$10.88M↓ | -$9.02M |
| Net Income | $50.18M↑ | -$127.50M↑ | -$183.16M↓ | -$71.64M↓ | $39.75M |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including dis...